Cambridge Healthcare Innovations (CHI) announced the availability of its dry powder inhaler (DPI) engine for clinical trials ...

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...

A man has shared how his beloved husband died after flu-like symptoms turned out to be deadly cancer. Brendan Hulse-Lewis had ...

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

On June 15 last year Kate, The Princess of Wales really put the ‘trooper’ into Trooping the Colour and appeared at the annual celebration of the sovereign’s birthday, despite being in the middle of ...

Cambridge Healthcare Innovations says its dry powder inhaler engine, Quattrii, can deliver large volumes of biologic and mRNA ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of ...

Cambridge Healthcare Innovations (CHI), a start-up designing and licensing revolutionary inhaler technology, has unveiled ...

Cambridge-based start-up rolls out industry-first inhaler for delivering large amounts of drug in a single inhalation, enabling next-gen inhaled biologics for novel therapiesCAMBRIDGE, 24 June 2025: ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Accord Healthcare’s Henlius-partnered Hetronifly ...

The central venous catheter market is projected to reach USD 3.09 billion in 2025 and is anticipated to grow to USD 5.86 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.6% ...

In recent years, cancer treatment has taken a big leap forward with a new, advancement known as CAR T-cell therapy. This may ...